Compare Bristol-Myers Squibb Co (BMY) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs NICE Ltd — how do they compare? Bristol-Myers Squibb Co trades at $63.8 (market cap $129.94B), while NICE Ltd trades at $98.41 (market cap $6.02B). The key difference: Bristol-Myers Squibb Co is far larger — about 21.6× NICE Ltd's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while NICE Ltd pays none. Which is the better fit depends on your goals.
| BMY | NICE | |
|---|---|---|
Market Cap | $129.94B | $6.02B |
Sector | Health | Technology |
52-Week High | $65.89 | $153.44 |
52-Week Low | $42.60 | $83.15 |
Enterprise Value | $163.92B | $5.75B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
NICE stock trades at $98.36, down 4.1% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $115. The company reported Q2 2026 earnings that beat expectations, with revenue growth of 7.6% year-over-year, and maintains strong profitability with a net income margin of 13.86%. Recent news highlights partnerships with Currys and RingCentral to enhance AI-powered customer engagement.
The outlook for NICE is positive, supported by consistent earnings beats, solid valuation metrics, and expanding AI integrations. Key risks include competitive pressures in the CX software space and potential volatility from macroeconomic factors. With no sell ratings from analysts and institutional interest, the stock presents a growth opportunity amid manageable risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
